Literature DB >> 1549852

Facilitation of specific tolerance induction in adult mice by RS-61443.

L Hao1, F Calcinaro, R G Gill, E M Eugui, A C Allison, K J Lafferty.   

Abstract

RS-61443 is an immunosuppressive agent that facilitates pancreatic islet allograft acceptance in two mouse strain combinations (BALB/c----CBA and C57Bl/6J----BALB/c). A remarkable feature of this agent is its ability to facilitate long-term graft acceptance after a short (30 days) period of treatment; following withdrawal of the agent 40-70% of islet allografts are maintained for an indefinite period. This long-term graft acceptance has been shown to result from specific tolerance induction in the recipient animal. The state of specific tolerance is an active rather than a passive form of tolerance, such as clonal deletion or anergy. Active tolerance induction is cyclosporine-sensitive, although cyclosporine enhances graft acceptance when used in combination therapy with RS-61443, this agent inhibits tolerance development under the influence of RS-61443.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1549852     DOI: 10.1097/00007890-199203000-00020

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  7 in total

Review 1.  The spectrum of action of new immunosuppressive drugs.

Authors:  A W Thomson
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

Review 2.  Xenobiotics, chimerism and the induction of tolerance following organ transplantation.

Authors:  C P Delaney; A W Thomson; A J Demetris; T E Starzl
Journal:  Ther Immunol       Date:  1994-06

Review 3.  New immunosuppressive drugs: mechanistic insights and potential therapeutic advances.

Authors:  A W Thomson; T E Starzl
Journal:  Immunol Rev       Date:  1993-12       Impact factor: 12.988

Review 4.  Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation.

Authors:  B Fulton; A Markham
Journal:  Drugs       Date:  1996-02       Impact factor: 9.546

Review 5.  Post-transplant diabetes mellitus. The role of immunosuppression.

Authors:  R M Jindal; R A Sidner; M L Milgrom
Journal:  Drug Saf       Date:  1997-04       Impact factor: 5.606

Review 6.  Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches.

Authors:  Rita Diehl; Fabienne Ferrara; Claudia Müller; Antje Y Dreyer; Damian D McLeod; Stephan Fricke; Johannes Boltze
Journal:  Cell Mol Immunol       Date:  2016-10-10       Impact factor: 11.530

7.  Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes.

Authors:  Peter A Gottlieb; Scott Quinlan; Heidi Krause-Steinrauf; Carla J Greenbaum; Darrell M Wilson; Henry Rodriguez; Desmond A Schatz; Antoinette M Moran; John M Lachin; Jay S Skyler
Journal:  Diabetes Care       Date:  2010-01-12       Impact factor: 17.152

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.